重度抑郁症药物治疗相关的磁共振研究进展
作者:
作者单位:

作者简介:

通讯作者:

基金项目:

首都卫生发展科研专项(首发2020-4-2125);北京市医院管理中心“青苗”计划 (QMS20211901)


Research advances of magnetic resonance imaging related to drug therapy of major depressive disorder
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    重度抑郁症(MDD)是一种高度异质性的精神疾病,抗抑郁药是 MDD 治疗的首选方案,其 中选择性 5- 羟色胺再摄取抑制剂(SSRI)及 5- 羟色胺和去甲肾上腺素再摄取抑制剂(SNRI)是临床中常 用的抗抑郁药物。但是目前临床用药主要依赖医生的临床经验,疗效的个体差异性较大,缺乏客观的 疗效评估指标。本文对SSRI和SNRI治疗中不同抗抑郁药物疗效相关的磁共振神经影像特征进行综述, 旨在寻找可预测或评估 SSRI、SNRI 类抗抑郁药疗效共有的和特异的神经影像学特征,为 MDD 患者的个 体化精准治疗、提高治疗效果提供参照。

    Abstract:

    Major depressive disorder (MDD) is a highly heterogeneous disease. Antidepressants are the preferred treatment for MDD, among which selective serotonin reuptake inhibitors (SSRI) and serotonin and norepinephrine reuptake inhibitors (SNRI) are commonly used antidepressants in clinical practice. However, currently clinical medication treatment mainly relies on the clinical experience of doctors, with significant individual differences in efficacy and a lack of objective efficacy evaluation indicators. This article reviews the magnetic resonance neuroimaging features related to the efficacy of SSRI and SNRI, aiming to find the common or specific neuroimaging features that can predict or evaluate the efficacy of SSRI and SNRI antidepressants, so as to provide reference for the individualized and precise treatment, expecting to improve antidepressant effect.

    参考文献
    相似文献
    引证文献
引用本文

侯西蔓,刘瑞,于爱红.重度抑郁症药物治疗相关的磁共振研究进展[J].神经疾病与精神卫生,2023,23(6).
DOI :10.3969/j. issn.1009-6574.2023.06.006.

复制
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2023-07-14